ConsulTech conducts its own R&D studies for pharmacologic and diagnostic purposes.

For this, we use the competences of CONELIS e.V., an association of experts in research, development and marketing tasks for the diagnostic-, pharma- and biotech-industry. We implement all our studies (non-clinical and clinical) extremely cost effective and efficient.

One of our R&D projects is GLIOMARK, which is co-funded by the European Commission through its Horizon 2020 SME Instrument program (GA no 673737). The project has a budget of more than 5.2 m € and is funded by 4.7 m € (one of the largest funded projects in the SME instrument).

In GLIOMARK, together with our Greek partner ProActina SA, a diagnostic kit is being developed to detect brain tumours and distinguish them from necrotic tissue.

You find more information on GLIOMARK at the project homepage here. We are commercialising the findings of this project via our daughter company Albega Medical GmbH.

Glioma therapy - theranostic

ConsulTech and Charité Berlin (Department of Nuclear Medicine) - both members of the ZIM funded NetPhasol network (ZKN0732202) start the successfully applied ZIM research project GLIOTHER (16KN073267) which aims at developing a new radiotherapy for glioblastoma.

This project is based on the results of the already successfully completed clinical studies on glioblastoma diagnostics, carried out within the framework of the own R&D project GLIOMARK (HORIZON 2020 funded EU project No 673737).

A central point of our development is the inclusion of the concept of theranostics, which allows the detection and treatment of tumours with essentially the same approach. Thus, a tumour diagnosis using such an approach provides reasonable assumption that the tumour will be effectively treated upon the therapeutic approach. Therefore, this concept represents the next step in personalized medicine.

Therapy of gliomas - Development of tumour-selective radiotherapeutic prodrugs for nuclear medicine therapy of glioblastomas (GLIOTAR)

In the GLIOTAR project, an innovative concept of radiopharmaceutical theranostic drugs is being developed. These substances are pharmacologically inactive and are only transformed into their actual active form (prodrugs) by a conversion step in the body. For this purpose, a therapeutic radioisotope is used, consisting of a metal complex, a flexible connecting molecule (linker) and a ligand, which is transported to a target structure in the brain tumour. There, after cell-specific activation, the prodrug is taken up into the cell and can develop its radiation effect. The cell specificity minimises the radiation exposure in other organs.

In the GLIOTAR projekt ConsulTech GmbH in collaboration with Charité - Universitätsmedizin Berlin, FU Berlin and the companies Chiracon GmbH and EPO GmbH identify compounds that are capable of binding to a radioisotope (nuclide) in order to obtain a so-called radioligand. This ligand can then specifically dock to a glioblastoma in the course of a radionuclide therapy and accumulate in the glioblastoma in order to be able to destroy the tumour in a targeted manner. Depending on which radioisotope is used, it enables the diagnosis or the destruction of the tumour. This so-called theranostic concept has the decisive advantage that the destructive radiation primarily acts in the tumour and side effects are minimised. This individual approach shows on the one hand whether the therapy is possible and on the other hand prevents ineffective therapy options - with all their side effects - for patients.

The project is described in more detail on a BMBF page.

Digital project management and collaboration

To enable flawless collaboration between partners of the research consortia which we support or we partner, respectively, we have developed and actively use our e-Col plattform.

e-Col is a "Content Collaboration Platform", which is based on Nextcloud and OnlyOffice. The underlying technology is used by German Federal Authorities for secure data exchange. The platform allows for secure file sharing, collaborative and simultaneous authoring of standrad office documents and offers a variety of project management tools e.g. calendar, chat, calls (with/without video) and more.

e-Col is being continuously enhanced; the actual version is 24.

Find out more on the product homepage: www.e-col.de

Anti-cancer low-energy radiation therapy

We have demonstrated that low-energy radiation which is usually employed in diagnostic medical devices such as computer tomographs has a therapeutic effect on cancer cells under certain circumstances.

ConsulTech investigates

• which cancer types are susceptible to this novel therapeutic approach
• which amount of radiation over time is required to achieve an optimal effect
• a novel medical device that directs an optimally oriented beam to the cancer in the body